PremiumRatingsDexcom’s Resilience Amid FDA Warning: Buy Rating Justified by Strong Long-Term Prospects Dexcom’s Resilience Amid Manufacturing Challenges: A Buy Rating Affirmation DexCom sees no material impact from warning letter on sales outlook PremiumThe FlyDexCom receives warning letter from FDA, sees no impact to FY25 guidance Dexcom’s Strong Market Position and Growth Potential Drive Buy Rating and Price Target Increase DexCom price target raised to $104 from $101 at Citi PremiumCompany AnnouncementsDexCom’s Optimistic Earnings Call: Growth Amid Challenges DexCom price target raised to $115 from $104 at Baird DexCom price target raised to $100 from $90 at Piper Sandler 
